Kernicterus Treatment Market Outlook 2024 : Expected Market Growth Rate, Major Driver And Segments | Pfizer Inc., F. Hoffmann-La Roche Ltd , Merck and Co. Inc., AbbVie Inc., Bayer AG, Novartis AG

"The new report published by The Business Research Company, titled ""Kernicterus Treatment Global Market Report 2024 - Market Size, Trends, And Global Forecast 2024-2033"", delivers an in-depth analysis of the leading size and forecasts, investment opportunities, winning strategies, market drivers and trends, competitive landscape, and evolving market trends.

As per the report, the kernicterus treatment market size has grown steadily in recent years. It will grow from $2.88 billion in 2023 to $2.98 billion in 2024 at a compound annual growth rate (CAGR) of 3.4%. The kernicterus treatment market size is expected to see steady growth in the next few years. It will grow to $3.29 billion in 2028 at a compound annual growth rate (CAGR) of 2.6%.

Download Free Sample Report @ https://www.thebusinessresearchcompany.com/sample.aspx?id=13470&type=smp

Significant Role Of Neonatal Jaundice Prevalence In Driving the Kernicterus Treatment Market Growth
The prevalence of neonatal jaundice is driving the growth of the kernicterus treatment market going forward. Neonatal jaundice, also known simply as jaundice in newborns, is a common and typically harmless condition characterized by the yellowing of a baby's skin and the whites of their eyes. Kernicterus treatment is commonly used for neonatal jaundice; it manages the symptoms and provides supportive care. This procedure removes blood from the baby and replaces it with blood with a lower bilirubin level, improving the affected child's quality of life. For instance, in August 2023, according to reports published by the National Library of Medicine, a US-based biomedical library, globally, about 1.1 million babies each year develop severe neonatal hyperbilirubinemia (neonatal jaundice). Furthermore, in February 2021, according to ClinMed International Library, a US-based publishing company, it was estimated that at least 114,000 infants die yearly from neonatal hyperbilirubinemia (neonatal jaundice). Therefore, the prevalence of neonatal jaundice is expected to propel the growth of the kernicterus treatment market.

Innovative Wearable Devices Revolutionizing Kernicterus Monitoring And Treatment In Infants
Major institutes operating in the kernicterus treatment market are developing innovative technological products, such as wearable devices to monitor jaundice accurately, that help gain a competitive advantage. A wearable device is a small, flexible patch placed on the body according to the treatment requirement. For instance, in March 2021, Yokohama National University, a Japan-based university, designed the first-ever wearable device to accurately monitor jaundice, a yellowing of the skin due to increased bilirubin levels in the blood that can result in severe medical conditions in infants. This wearable sensor for infants can constantly measure bilirubin to achieve the intricate balance of administering the accurate amount of blue light required to neutralize the correct bilirubin levels. Moreover, it is a small, flexible patch that is placed on the infant's chest, and it transmits data to a smartphone or computer, where doctors or parents can monitor it. Also, it is more accurate and convenient than traditional methods of monitoring jaundice, such as blood tests.

The kernicterus treatment market covered in this report is segmented -

1) By Treatment: Phototherapy, Intravenous Immunoglobulins (IVIG), Blood Transfusion, Medication, Other Treatments
2) By Symptoms: Jaundice, Unusual Eye Movements, Vomiting, Fever, Poor Feeding, Apnoea, Irritability, Seizures, Sleepiness, Other Symptoms
3) By Dosage: Injection, Solution, Other Dosages
4) By End-Users: Clinic, Hospital, Other End-Users

Buy Now & Get Exclusive Discount on this Report, Checkout link @
https://www.thebusinessresearchcompany.com/Discount?id=13470&type=discount

Major companies operating in the kernicterus treatment market report are Pfizer Inc., F. Hoffmann-La Roche Ltd , Merck and Co. Inc., AbbVie Inc., Bayer AG, Novartis AG, AstraZeneca plc., Abbott Laboratories, Sanofi SA, GlaxoSmithKline plc, Takeda Pharmaceutical Company Limited, Johnson and Johnson Private Limited, Baxter International Inc., Grifols S.A, Sun Pharmaceutical Industries Ltd., Dr. Reddy's Laboratories Ltd., Alembic Pharmaceuticals Limited, Lupin Pharmaceuticals Inc., CSL Limited, Glenmark Pharmaceuticals Ltd., Cipla Inc., Torrent Pharmaceuticals Ltd., Octapharma Brasil Ltda, Kedrion S.p.A, Biotest AG, Wockhardt Ltd., Mylan N.V., Cadila Healthcare Ltd., Teva Pharmaceutical Industries Ltd., China Biologic Products Holdings Inc.

Contents of the report:
1. Executive Summary
2. Kernicterus Treatment Market Report Structure
3. Kernicterus Treatment Market Trends And Strategies
4. Kernicterus Treatment Market - Macro Economic Scenario
5. Kernicterus Treatment Market Size And Growth
…..
27. Kernicterus Treatment Market Competitor Landscape And Company Profiles
28. Key Mergers And Acquisitions
29. Future Outlook and Potential Analysis
30. Appendix

Explore the report store to make a direct purchase of the report @ https://www.thebusinessresearchcompany.com/report/kernicterus-treatment-global-market-report

Contact Us:
The Business Research Company
Europe: +44 207 1930 708
Asia: +91 88972 63534
Americas: +1 315 623 0293
Email: info@tbrc.info

Follow Us On:
LinkedIn: https://in.linkedin.com/company/the-business-research-company
Twitter: https://twitter.com/tbrc_info
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ "

Learn More About The Business Research Company

The Business Research Company (www.thebusinessresearchcompany.com) is a leading market intelligence firm renowned for its expertise in company, market, and consumer research. With a global presence, TBRC's consultants specialize in diverse industries such as manufacturing, healthcare, financial services, chemicals, and technology, providing unparalleled insights and strategic guidance to clients worldwide.

This release was published on openPR.